Compare Mesoblast Limited (MESO) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Invesco S&P 500 Low Volatility ETF — how do they compare? Mesoblast Limited trades at $14.13 (market cap $1.75B), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $6.94B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 4× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 1,663,703). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| MESO | SPLV | |
|---|---|---|
Market Cap | $1.75B | $6.94B |
Volume | 239,027 | 1,663,703 |
Sector | Health | — |
52-Week High | $20.96 | $77.97 |
52-Week Low | $13.19 | $70.30 |
Typical Hold Time | 14 Days | 123 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SPLV trades at $71.99, up 1.08% with a bearish technical outlook from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 provide income support, while technical indicators show mixed signals with neutral oscillators.
Outlook remains cautious due to sector headwinds and unappealing growth-adjusted valuation. The fund's low-volatility focus offers defensive positioning amid market uncertainty, though continued underperformance relative to broader market indexes presents near-term challenges for total return investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
